

## Special Issue

# Analysis and Modification of Existing Vaccines for the Development of Next-Generation Vaccines

### Message from the Guest Editor

Dear colleagues, The development of the first vaccine by Edward Jenner, “the father of immunology”, has proven to be one of the greatest innovations, saving countless lives. However, the emergence or recurrence of pathogens is an ongoing threat to humans, not least with the recent occurrence of COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although the development and distribution of a vaccine against SARS-CoV-2 are urgently needed, other diseases should not be ignored. In this regard, the small modification of existing vaccines is likely to prove efficient for the development of versatile vaccines that are more stable for storage and represents an important step in the direction of the production of next-generation vaccines. This Special Issue will focus on the analysis of the mode of action of current vaccines and their modification for the development of next-generation vaccines. The submission of articles covering the following research areas is encouraged:

- Experimental characterization of vaccine;
- Proof of concept of next-generation vaccines.

---

### Guest Editor

Dr. Takashi Imai

1. Department of Microbiology, Saitama Medical University, Saitama, Japan
2. Department of Infectious Diseases and Host Defense, Gunma University, Gunma, Japan

---

### Deadline for manuscript submissions

closed (30 June 2021)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.2  
CiteScore 8.9  
Indexed in PubMed



[mdpi.com/si/60721](https://mdpi.com/si/60721)

*Vaccines*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.2  
CiteScore 8.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the second half of 2024).